done by comparison one of the studies 2 investigating pressure reproducibility for 551 different short-stretch bandage appliers in comparison to the 21 appliers. 5 To evaluate the stiffness, a dynamic PicoPress measurement was performed.
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Characterization and Pattern of Payments to Vascular Surgeons in Regards to Novel Oral Anticoagulants Factor 10A Inhibitors
Brandon Brockbank, Michael F. Amendola.
1 Virginia Commonwealth University, Richmond, Va
Objectives: The Open Payments program requires reporting of payments to licensed physicians and has linked information to type of medication that is being used. Our group set out to examine the payments to vascular surgeons in regards to two leading factor 10A inhibitors.
Methods: A descriptive analysis of the 2015 dataset from the publicly available Open Payments database was undertaken. All payments made to vascular surgeons as they related to Xarelto (Janssen Pharmaceuticals) and Eliquis (Pfizer and Bristol-Myers Squibb) were collected and analyzed. Payments related to royalties, stock payments, grants, current or prospective ownership, and honorarium were excluded.
Results: Total payments in 2015 made to vascular surgeons were $12,674,746.18 of which 5.5% or $694,208.80 were related to factor 10A inhibitors. There were 1535 payments for 433 unique physicians for Xarelto and 1962 payments for 579 physicians for Eliquis. Mean payments for each drug was $143.7 6 $582.4 for Xarelto and $241.6 6 $698.0 for Eliquis (P ¼ .0001, Student t-test). Payment on average per physician was $509.08 for Xarelto and $818.27 for Eliquis.
Conclusions: Total payments for factor 10A inhibitors were in the minority of total payments to vascular surgeons as captured by the Open Payments database. The majority of payments were made on behalf of Eliquis, with a significantly greater mean payment. These data should inform the vascular surgery community at large of the types and amounts of influence that the makers of each of these medications are spending to influence practice patterns.
Author Disclosures: M. F. Amendola: Nothing to disclose; B. Brockbank: Nothing to disclose.
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Reintroduction of the Gritti-Stokes (Above-Knee) Amputation Objectives: Patients with inadequate soft tissue coverage or insufficient vascular perfusion in the distal leg, which eliminates them as a candidate for a below-knee amputation, are traditionally offered a more debilitating and morbid above-knee amputation (AKA). According to our study, this population of patients may benefit from the Gritti-Stokes amputation (GSA) as a superior option to a classic AKA.
Methods: In all GSA operations performed, a fish-mouth incision was fashioned below the tibial tuberosity into the popliteal crease, resulting in anterior and smaller posterior soft tissue flaps. The patellar tendon was transected at the tibial tuberosity and flipped over, exposing the posterior patellar surface after the joint capsule was entered. The femur was transected at a 45 angle posteriorly. The patellar's posterior surface was shaved down flat to the medulla, allowing it to be secured to the end of the femur without shifting. The fascia, dermis, and skin were then closed in the standard tension free manner.
Results: In our series of nine GSA operations in eight patients, intraoperative outcomes were notable for lower estimated blood losses then the classic AKA amputation and comparable operative times. Postoperative outcomes showed low complication rates and increased limb function, with preservation of the anterior thigh muscular attachments. Postoperative complications were limited to only one case of a stump infection, which was treated and subsequently healed completely. No cases of mortality were encountered.
Conclusions: Our experience with a small series of GSA has yielded promising results, including decreased blood loss and increased function compared to the standard AKA. We also anticipate that these patients will require less time to mature their stump then the traditional belowknee amputation AKA, benefiting from the prethickened skin and subcutaneous tissues overlying the patella. Recent advancements in sliding 
